Evaluation of long-acting cabotegravir safety and pharmacokinetics in pregnant women in eastern and southern Africa: a secondary analysis of HPTN 084

By sjmartinez • January 3, 2025

Delany-Moretlwe S, Hanscom B, Guo X, Nkabiito C, Mandima P, Nahirya PN, Mpendo J, Bhondai-Mhuri M, Mgodi N, Berhanu R, Farrior J, Piwowar-Manning E, Ford SL, Hendrix CW, Rinehart AR, Rooney JF, Adeyeye A, Landovitz RJ, Cohen MS, Hosseinipour MC, Marzinke MA; HPTN 084 Study Team. Evaluation of long-acting cabotegravir safety and pharmacokinetics in pregnant women in eastern and southern Africa: a secondary analysis of HPTN 084. J Int AIDS Soc. 2025 Jan;28(1):e26401. doi: 10.1002/jia2.26401. PMID: 39748218.

Tags: Cabotegravir, HIV prevention, Infectious Diseases, long‐acting, pregnancy, PrEP, Publications, Women

Machine learning models predict long COVID outcomes based on baseline clinical and immunologic factors

Doni Jayavelu N, Samaha H, Wimalasena ST, Hoch A, Gygi JP, Gabernet G, Ozonoff A, Liu S, Milliren CE, Levy O, Baden LR, Melamed E,[...]

Can chlorhexidine bathing reduce Candidozyma auris shedding?

Gussin GM, Singh RD, Kleinman K, Saavedra R, Shimabukuro JA, Flores EA, Miller LG, Bittencourt CE, Huang SS. Can chlorhexidine bathing reduce Candidozyma auris shedding?[...]

Heart Failure Risk and Events in People With HIV: The Randomized Trial to Prevent Vascular Events in HIV (REPRIEVE)

Bloomfield GS, Watanabe M, McCallum S, Aberg JA, Awwad A, Campbell TB, Cespedes MS, Chu SM, Currier JS, Diggs MR, Sponseller CA, Fichtenbaum CJ, Lu[...]